P/B
2,7
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
$446.2M
Market Cap • 9/11/2026
2018
(8 years)
Founded
2024
(2 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
3,1
EPS
—
Market Cap
Market Cap
446,2M
EV
279,8M
EV/Revenue
0
EV/EBITDA
-1,8
EV/EBIT
-1,8
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-27,3%
Total Yield
-27,3%
Payout
0%
Retained Earnings
-502,9M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
18,8%
Capex/OCF
-0,2%
SBC/OCF
—
% PPE
4,2%
% Goodwill
0%
ROE
—
ROIC
—
Leverage
N.D./EBITDA
1,1
Debt/Equity
0%
Current Ratio
9,1
Quick Ratio
8,7
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!